Coherus BioSciences now has two biosimilars pending before the US Food and Drug Administration, after Formycon/Bioeq submitted to the agency their biosimilar Lucentis (ranibizumab) candidate for which Coherus holds US commercialization rights.
“Our next expected biosimilar launch is CHS-201, our Lucentis biosimilar candidate,” confirmed company chairman, president and CEO Denny Lanfear, speaking...